



PROTEOGLYKANY





Aggrecan



Glykokonjugaty vyskytující se volně v ECM, navázané na buněčném povrchu a v intracelulárních váčcích.


- Proteinové jádro (serin – glycín): OH skupina serinu váže xylosu
- Trisacharidová spojka: xylosa – galaktosa – galaktosa
- Glykosaminoglykanový řetězec: nevětvený, vysokomolekulární, složený z disacharidových jednotek



BIOSYNTÉZA HEPARAN SULFÁT PROTEOGLYKANŮ

Třístupňový proces probíhající v Golgiho aparátu:



- I. Iniciace: připojení trisacharidového linku k OH skupině serinu (Xyl transferáza, Gal transferáza I-II) a následné připojení první glukuronové kyseliny (GlcA transferáza)
- II. Polymerace: zahrnuje postupné přidávání N-acetyl glukosaminu a glukuronové kyseliny. Vzniklý řetězec obsahuje 50 – 150 disacharidových jednotek.




III. Modifikace:

a) glukuronová kys. → induronová kys. (C-5 epimerace)
 → sulfonace na C-2 (+ SO³⁻)

b) N-acetylglukosamin → deacetylace aminoskup.
 → sulfonace na C-3, C-6





Current Opinion in Structural Biology

Modification reactions in GAG biosynthesis. (a) In HS biosynthesis the modification reactions are initiated by N-deacetylation/N-sulfation of selected GlcNAc residues. Subsequent modifications occur in N-sulfated regions of the polysaccharide. Note that 6-O-sulfation may occur to GlcNAc residues adjacent to N-sulfated disaccharides. (b) In DS biosynthesis, 4-O-sulfation takes place immediately after epimerization. 2-O-sulfation may then occur. In CS biosynthesis, 6-O-sulfation of GalNAc and GalNAc(4S) are carried out by a separate enzymes. (c) During KS biosynthesis, 6-O-sulfation occurs to non-reducing terminal GlcNAc residues before further elongation. Sulfation of Gal residues may occur during or after chain elongation. β 1,4Gal-T1, β 1,4-galactosyltransferase 1; β 1,3GlcNAc-T, β 1,3-N-acetylglucosaminyltransferase. Modified from [44*].

Table 1

GAG sulfotransferases.



Enzyme	Abbreviation	Predominant substrate (target in bold)	Predominant expression patterns* in human (left) and mouse (right) tissues		Refs
Chondroitin/dermatan sulfate					
Chondroitin 4-O-sulfotransferase-1	C4ST1	-GlcA-GalNAc-	Broad (hematopoetic tissues, peripheral blood leukocytes)	Broad (brain, kidney)	[25,26]
Chondroitin 4-O-sulfotransferase-2	C4ST2	-GlcA-GalNAc-	Broad		[26]
Chondroitin 4-O-sulfotransferase-3	C4ST3	-GlcA-GalNAc-	Liver		[27]
Dermatan 4-O-sulfotransferase-1	D4ST1	-IdoA-GalNAc-	Broad (placenta)		[28]
Chondroitin 6-O-sulfotransferase [†]	C6ST (GST0, CS6ST)	-GlcA-GalNAc-	Broad (aorta, testis)	Broad (spleen, lung eye)	[30,37*,59]
Chondroitin 6-O-sulfotransferase-2 [‡]	C6ST2 (GST5, GlcNAc6ST-4)	-GlcA-GalNAc	Broad (heart, spleen, ovary)	Broad (kidney)	[34]
Chondroitin 4-sulfate 6-O-sulfotransferase	GalNAc4S-6ST	-GlcA-GalNAc4S-			[38]
Galactosaminyl uronyl 2-O-sulfotransferase	CS/DS2ST	-GlcA-GalNAc6S- -IdoA-GalNAc±4S	Broad		[40]
Keratan sulfate					
Keratan sulfate Gal 6-O-sulfotransferase	KSGal6ST (GST1)	-Gal-GlcNAc-	Brain		[42]
GlcNAc 6-O-sulfotransferase	GlcNAc6ST1 (GST2)	GlcNAc-Gal-	Broad	Broad	[32,60]
GlcNAc 6-O-sulfotransferase	GlcNAc6ST2 (HEC-GlcNAc6ST GST3, LSST)	GlcNAc-Gal-	High endothelial venules		[61,62]
Corneal GlcNAc 6-O-sulfotransferase, mouse intestinal GlcNAc 6-O-sulfotransferase [§]	GlcNAc6ST-5 (C-GlcNAc6ST, GST4β)	GlcNAc-Gal-	Cornea, spinal cord, trachea		[45,46]
Heparan sulfate/heparin					
N-deacetylase/N-sulfotransferase 1	NDST1	-GlcA-GlcNAc-	Broad	Broad	[9,63]
N-deacetylase/N-sulfotransferase 2	NDST2	-GlcA-GlcNAc-	Broad	Broad	[9,63]
N-deacetylase/N-sulfotransferase 3	NDST3	-GlcA-GlcNAc-	Broad	Adult brain, fetal tissues	[9]
N-deacetylase/N-sulfotransferase 4	NDST4	-GlcA-GlcNAc-		Adult brain, fetal tissues	[9]
Heparan sulfate 2-O-sulfotransferase	2-OST (HS2ST)	-HexA-GlcNS-	Broad		[13]
Heparan sulfate 6-O-sulfotransferase 1	6-OST1 (HS6ST-1)	-HexA±2-GlcNS/Ac-	Broad	Broad (liver)	[15-17]
Heparan sulfate 6-O-sulfotransferase 2	6-OST2 (HS6ST-2)	-HexA±2S-GlcNS/Ac-	Brain	Broad (brain, spleen)	[15-17]
Heparan sulfate 6-O-sulfotransferase 2S [¶]	6-OST2S (HS6ST-2S)	-HexA±2S-GlcNS/Ac-	Ovary, placenta, fetal kidney		[17]
Heparan sulfate 6-O-sulfotransferase 3	6-OST3 (HS6ST-3)	-HexA±2S-GlcNS/Ac-		Broad	[15,16]
Heparan sulfate 3-O-sulfotransferase 1	3-OST1	-GlcA-GlcNS±6S-	Broad (kidney, brain)		[18]
Heparan sulfate 3-O-sulfotransferase 2	3-OST2	-HexA2S-GlcNS-	Brain		[18,64]
Heparan sulfate 3-O-sulfotransferase 3A	3-OST3A	-IdoA2S-GlcNH ₂ ±6S-	Broad (heart, placenta)		[18,64]
Heparan sulfate 3-O-sulfotransferase 3B	3-OST3B	-IdoA2S-GlcNH ₂ ±6S-	Broad (liver, placenta)		[18,64]
Heparan sulfate 3-O-sulfotransferase 4	3-OST4	Unknown	Brain		[18]
Heparan sulfate 3-O-sulfotransferase 5	3-OST5	-GlcA-GlcNS±6S-, -IdoA2S-GlcNS±6S-	Brain, spinal cord		[19,20]

*Lower levels of transcript may be present in other tissues as well. Tissues within parenthesis show the highest expression levels. [†]Has also weak KS Gal 6-O-sulfotransferase activity. [‡]This enzyme has also been characterized as a GlcNAc 6-O-sulfotransferase (GlcNAc6ST4) [33,35]. [§]Mouse intestinal GlcNAc6ST has the same activity as human corneal GlcNAc6ST and is likely to produce mouse corneal KS [45]. [¶]Splice forms of 6-OST2 so far only described in humans.



HEPARANSULFÁT PROTEOGLYKAN (HSPG)

Podle proteinové struktury rozlišujeme III. typy HSPG:

- A) Syndecan: transmembránový protein, který může nést HS nebo CS řetězce
- B) Glypican: protein ukotvený v membráně přes glykosylfosfatidylinositolovou kotvu, který nese HS řetězce
- C) Perlecan: sekretovaný proteoglykan s HS řetězci, volně v ECM




Dyssegmental dysplasia (Perlecan loss-of-function)




Glucuronyl C5-epimerase (HS lack Iduronic acid)


A urogenital tract



B lung




D skeleton



E



F







Figure 1. Low and High Affinity Binding of ^{125}I -bFGF to Wild-Type and HS-Deficient Cells

Cells were incubated for 2 hr at 4°C with a saturating (10 ng/ml) concentration of ^{125}I -bFGF. (A) Low affinity binding. (B) High affinity binding. NIH-3T3 cells, mouse embryonal fibroblasts known to have both low and high affinity FGF receptors, were used as positive controls; CHO-KI, parental, wild-type CHO cells; clones 803 and 677, CHO cells that lack cell surface HSPGs. The 677 cells also overexpress chondroitin sulfate. Clone 606 is a line of HS-N-sulfotransferase-deficient cells that express undersulfated cell surface HSPGs (Barne and Esko, 1989). Results represent the mean values in one of at least two independent experiments.

TRANSCRIPTION FACTORS

- ultimate effectors of the outside-in intercellular signaling
- one of the most important molecules in shaping of the embryo
- classified in families by DNA-binding domain

1. HOMEODOMAIN FACTORS


Homeodomain – 60aa sequence that interact with DNA, encoded by homeobox in the particular gene. Many homeobox genes regulate segment identity.

Homeotic genes cause **homeosis** – a transformation of one whole segment into another related one, such as antenna into leg.

Segment polarity genes – basic shape of segment, same for all segments.

Homeotic selector genes – control the differences in segment development via initiation of future developmental pathways in each segment.

Anterior



Antennapedia complex

<i>lab</i>	labial
<i>pb</i>	proboscidea
<i>Dfd</i>	Deformed
<i>Scr</i>	Sex combs reduced
<i>Antp</i>	Antennapedia

Posterior


bithorax complex

<i>Ubx</i>	Ultrabithorax
<i>abd-A</i>	abdominal-A
<i>Abd-B</i>	Abdominal-B

Antennapedia








Bithorax



Chinook






2. LIM-HOMEODOMAIN PROTEINS

Two LIM domains fused to DNA-binding homeodomain
Islet-1

E9.5




3. PAX PROTEINS

DNA binding region: paired domain with 6 α -helical segments


Pax6 (paired box gene 6)

- se - surface ectoderm
- ms –mesenchymal-like cells
- rpe – pigmented retinal epithelium
- ret – retina
- os – optic stalk
- ov- optic vesicle
- nc – nasal cavity
- ls -lens

wt



Pax6^{-/-}




200 μ m

E11.5

4. ZINC-FINGER PROTEINS

Bind DNA via zinc-finger motif




Dracula fish – loss-of-function mutation in GATA1 – impaired erythroid differentiation


5. NUCLEAR RECEPTOR SUPERFAMILY

Intracellular receptor that function as transcription factors. Lipophilic ligands: steroids, thyroid hormone, retinoid acid. Inactive – Hsp90-bound in cytoplasm, complexed with ligand, - nuclear.


Retinoid acid signaling in limiting the cardiac progenitor pool



6. BASIC HELIX-LOOP-HELIX (bHLH) FACTORS



MyoD^{+/−} Myf-5^{+/−}





MyoD^{−/−} Myf-5^{−/−}



Contain basic DNA binding region and hydrophobic helix-loop-helix region responsible for dimerisation


α -actin IHC
(smooth and striated muscle fibers)



desmin IHC
(skeletal muscle fibers, myoblast-like cells)


7. T-BOX FACTORS

DNA binding domain derived from the prototype gene called transcription factor T.
Limb identity factors *Tbx4* and *Tbx5*



8. HIGH MOBILITY GROUP (HMG)-box FACTORS

Operate via bending DNA to bring regulatory sites with transcriptional complex
Sox9 (Sry-Box9) – master inducer of cartilage





9. SRY (sex determining region Y)

Table 1 • Sex reversal observed in XX transgenic mice at 14.5 dpc


Construct	Embryos transferred	Embryos recovered	XX transgenic	Sex-reversed	% sex-reversed
L741	2,400	145	6	4	67
SrySt1	3,500	138	4	2	50
SryStop1	3,000	239	13	0	0
SryStop2	3,200	320	20	0	0
SryStop2Rev	1,000	82	4	3	75

The number of embryos transferred is approximate.



10. RUNT DOMAIN-CONTAINING FACTORS

Runx2 (Runt-related transcription factor 2)



2006- INDUCIBLE PLURIPOtent CELLS (iPS)

Cell

Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors

Kazutoshi Takahashi¹ and Shinya Yamanaka^{1,2,*}

¹Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

²CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan

*Contact: yamanaka@frontier.kyoto-u.ac.jp

DOI 10.1016/j.cell.2006.07.024

SUMMARY


Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem (ES) cells. Little is known about factors

or by fusion with ES cells (Cowan et al., 2005; Tada et al., 2001), indicating that unfertilized eggs and ES cells contain factors that can confer totipotency or pluripotency to somatic cells. We hypothesized that the factors that play important roles in the maintenance of ES cell identity also play pivotal roles in the induction of pluripotency in somatic cells.




Oct3/4
Sox2
c-Myc
Klf4


B



A



C



D




Table 1

Summary of reprogramming studies

Species	Cell type	Factors	Selection strategy	Reference study
Mouse	MEFs and tail tip fibroblasts	Oct4, Sox2, Klf4, and c-Myc	Fbx15-neo	[8**]
	MEFs		Nanog-puro	[12*]
	MEFs		Nanog-puro	[11*]
	MEFs and tail tip fibroblasts	Oct4, Sox2, and Klf4	Nanog- or Oct4-neo	[13*]
	MEFs		Oct4-GFP	[16]
	MEFs and tail tip fibroblasts	Oct4, Sox2, and Klf4	Nanog-puro	[45*]
Human	HDF	Oct4, Sox2, Klf4, and c-Myc	Morphology	[17**]
	HFLS			
	BJs			
	Adult fibroblasts	Oct4, Sox2, Nanog, and LIN28	Morphology	[18**]
	Foreskin fibroblasts			
	H1F cells	Oct4, Sox2, Klf4, and c-Myc	Oct4-neo	[19**]
	Fetal fibroblasts		Morphology	
	H1F cells	Oct4, Sox2, Klf4, c-Myc, hTert, and SV40 large T	Oct4-neo	
	MSCs		Morphology	
	Adult fibroblasts			
H1F cells		Oct4, Sox2, and Klf4	Oct4-neo	
		Oct4, Sox2, and c-Myc		

HDF, human dermal fibroblasts; HFLS, human fibroblast-like synoviocytes; BJ, cell line derived from neonate fibroblasts; H1F, ES cell-derived fibroblast; MSCs, mesenchymal stem cells.

ARTICLES

***In vivo* reprogramming of adult pancreatic exocrine cells to β -cells**

Qiao Zhou¹, Juliana Brown², Andrew Kanarek¹, Jayaraj Rajagopal¹ & Douglas A. Melton¹

